Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells
- PMID: 1908442
- DOI: 10.1002/ijc.2910490115
Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells
Abstract
Nude mice were inoculated with CHO/IFN-gamma cells, a line of Chinese hamster ovary tumor cells, that had been genetically engineered to produce murine IFN-gamma. Severe cachexia, as evident from body weight loss and reduced food intake, occurred in these mice, but not in those injected with CHO/control cells, i.e. the original, non-IFN-gamma-producing line. The essential role of IFN-gamma in the pathogenesis of cachexia was confirmed by the demonstration that monoclonal antibodies (MAbs) against IFN-gamma, given prior to injection of the tumor cells, prevented cachexia. In addition to IFN-gamma, the presence of the tumor cells was also required for cachexia to develop. As evident from pair-feeding experiments, reduced food intake could only partially account for the rapid and extensive body-weight loss. Cachexia was characterized by a marked reduction in the amount of interscapular fat tissue. Injected tumor cells exclusively invaded intraperitoneal adipose tissue and elicited an inflammatory cell infiltrate, indicating that interscapular fat loss was due to humoral factors. Our data suggest that, among the humoral factors responsible for cancer-associated cachexia, IFN-gamma plays a prominent role.
Similar articles
-
The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia.Cancer Res. 1991 May 1;51(9):2302-6. Cancer Res. 1991. PMID: 1901758
-
Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.Cancer Res. 2000 Oct 1;60(19):5488-93. Cancer Res. 2000. PMID: 11034092
-
Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia.Eur J Cancer. 1991;27(2):182-7. doi: 10.1016/0277-5379(91)90483-t. Eur J Cancer. 1991. PMID: 1827286
-
Cancer anorexia-cachexia syndrome: are neuropeptides the key?Cancer Res. 1999 Sep 15;59(18):4493-501. Cancer Res. 1999. PMID: 10493494 Review.
-
Cancer cachexia.Curr Opin Gastroenterol. 2010 Mar;26(2):146-51. doi: 10.1097/MOG.0b013e3283347e77. Curr Opin Gastroenterol. 2010. PMID: 19918173 Review.
Cited by
-
Are cytokines possible mediators of cancer cachexia?Surg Today. 1996;26(7):467-75. doi: 10.1007/BF00311551. Surg Today. 1996. PMID: 8840426 Review.
-
Inflammation and Skeletal Muscle Wasting During Cachexia.Front Physiol. 2020 Nov 19;11:597675. doi: 10.3389/fphys.2020.597675. eCollection 2020. Front Physiol. 2020. PMID: 33329046 Free PMC article. Review.
-
JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.Cell Rep. 2020 Nov 17;33(7):108407. doi: 10.1016/j.celrep.2020.108407. Cell Rep. 2020. PMID: 33207208 Free PMC article.
-
The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia.Br J Cancer. 2005 Mar 14;92(5):876-81. doi: 10.1038/sj.bjc.6602404. Br J Cancer. 2005. PMID: 15714206 Free PMC article.
-
Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides.ACS Pharmacol Transl Sci. 2022 Apr 14;5(5):344-361. doi: 10.1021/acsptsci.1c00270. eCollection 2022 May 13. ACS Pharmacol Transl Sci. 2022. PMID: 35592439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials